Cargando…
An anti-cancer derivative of butyric acid (pivalyloxmethyl buterate) and daunorubicin cooperatively prolong survival of mice inoculated with monocytic leukaemia cells.
A derivative of butyric acid, pivalyloxymethyl butyrate (AN-9), inhibited the proliferation and induced apoptosis of mouse monocytic leukaemia Mm-A cells, although sodium butyrate, but not AN-9, induced differentiation of the cells. AN-9 and DNA-specific antineoplastic agents synergistically inhibit...
Autores principales: | Kasukabe, T., Rephaeli, A., Honma, Y. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group|1
1997
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063395/ https://www.ncbi.nlm.nih.gov/pubmed/9062406 |
Ejemplares similares
-
Acquired resistance to daunorubicin in a patient with acute myelogenous leukaemia.
por: Smith, B. J., et al.
Publicado: (1976) -
Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia
por: Blair, Hannah A.
Publicado: (2018) -
Who is to blame? Perspectives of caregivers on barriers to accessing healthcare for the under-fives in Butere District, Western Kenya
por: Opwora, Antony S, et al.
Publicado: (2011) -
Daunorubicin pharmacokinetics and the correlation with P-glycoprotein and response in patients with acute leukaemia.
por: Galettis, P., et al.
Publicado: (1994) -
Correction to: Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia
por: Blair, Hannah A.
Publicado: (2018)